The landscape of PD-L1, PD-L2, and PD-1 in the endometrial tumor compartment and endometrial TME compartment can lead to PD-L1/2-PD-1-mediated immune checkpoint inhibition, as represented in Figure 9. This evidence concerns the gene CD274 and endometrium neoplasm.